Upstream Bio, Inc. 8-K

What Happened

• On May 13, 2026, Upstream Bio, Inc. announced its quarterly financial results and business highlights for the quarter ended March 31, 2026. The company furnished a press release as Exhibit 99.1 to the Form 8‑K. The report was signed by E. Rand Sutherland, M.D., Chief Executive Officer.

Key Details

• Filing date: May 13, 2026 (Form 8‑K, Item 2.02 and Item 9.01).
• Reporting period: Quarter ended March 31, 2026 (Q1 2026 quarterly results).
• Press release announcing the earnings and business highlights is furnished as Exhibit 99.1.
• Report is signed by E. Rand Sutherland, M.D., Chief Executive Officer; an Interactive Data File (Exhibit 104) is included.

Why It Matters

• This 8‑K formally notifies investors that Upstream Bio has released its quarterly results (earnings, revenue and related business updates) — investors should read the furnished press release (Exhibit 99.1) for the specific financial figures and management commentary.
• Quarterly results can affect valuation and near‑term trading; reviewing the press release and the company’s upcoming periodic filings (e.g., Form 10‑Q) will provide the full financial detail needed to assess performance.